Fact Source: Financial Supervisory Service DART / 2026-02-10
Disclosure Type: Amendment to Major Management Matters Related to Investment Judgment
💡 3-Second Summary
Celltrion has filed a revised disclosure regarding its European Phase 3 clinical trial protocol amendment application for ‘CT-P55’, revealing that the total number of clinical trial subjects is officially confirmed at 153 following the lifting of a business confidentiality restriction.
📊 1. [Summary of Key Disclosure Content and Major Figures]
- Date of Amendment: February 10, 2026
- Target Document: Major Management Matters Related to Investment Judgment originally submitted on October 27, 2025.
- Reason for Amendment: Expiry and lifting of withheld disclosure items (business confidentiality restriction).
[Major Rectifications and Updates]
- Number of Clinical Trial Subjects (Agenda 2, Clause 7): Changed from ‘Confidential’ to ‘153 patients’.
- Condition for Lifting Withheld Items: The initial confidentiality period was set to last until both Part 1 (assessment of trial design) and Part 2 (assessment of clinical sites) of the Phase 3 protocol amendment application were fully approved by the authority. As this target threshold has been achieved, the amended report was issued.
[Finalized Details of the Amended Phase 3 Application]
- Regulatory Authority: European Medicines Agency (EMA)
- Initial Application Date: October 27, 2025 (Local time basis)
- Trial Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Clinical Trial to Compare the Efficacy and Safety of CT-P55 and Cosentyx in Patients with Moderate to Severe Plaque Psoriasis
- Trial Stage & Indication: Global Phase 3 Clinical Trial / Plaque psoriasis
- Trial Implementation Method: 153 subjects / 56 weeks duration / Randomized, active-controlled, double-blind design
- Objective of Protocol Amendment: Adjustment of sample size due to changes in regulatory approval strategy.
📈 2. [Expert Perspective: What This Disclosure Means for Investors]
This amendment disclosure marks a programmatic update indicating that the operational parameters for Celltrion’s next-generation biosimilar pipeline ‘CT-P55’ in Europe have achieved localized regulatory milestones, effectively removing an information bottleneck. By satisfying the requirements to lift the business confidentiality clause, the exact scale of the trial architecture—specifically the cohort size of 153 subjects—has been made transparent, which stabilizes data reliability.
As noted in the regulatory notes, the driving factor behind this protocol amendment is a calculated adjustment of the sample size stemming from a modified regulatory approval strategy. Aligning the structural cohort to 153 patients creates the formal framework required to systematically execute the 56-week comparative biosimilarity study against the original reference product, Cosentyx. However, because the primary document strictly cautions that the statistical probability of an investigational clinical asset securing final product authorization is approximately 10%, this structural clarity should be analyzed as a potential impact on operational velocity rather than a guarantee of ultimate clinical success. Investors could prudently benchmark future progress against the steady enrollment and longitudinal readouts of these 153 defined subjects over the medium term.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion’s European regulatory roadmap for CT-P55 has reached an advanced degree of transparency with the lifting of this data-withholding clause, clarifying the target cohort size at 153 subjects. The explicit statement linking the amendment to an altered regulatory strategy suggests that the executive team has re-calibrated the trial scale to align precisely with European Medicines Agency frameworks for optimized review tracking. While removing this informational opacity is a constructive governance adjustment, the fundamental clinical hurdles—notably the historical 10% industry-wide probability for final drug commercialization—remain active risk inputs. Analytical focus must now transition away from regulatory assumptions toward tracking the execution timeline of the 56-week study across the confirmed 153-patient population.
📢 Disclaimer and Source Information
Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).
Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
